IFN-β-induced alteration of VSV protein phosphorylation in neuronal cells

Viral Immunology

Volumn 22, Issue 6, 2009, Pages 353-369

  D'Agostino, Paul M ^a   Amenta, Jessica J ^a   Reiss, Carol Shoshkes ^a,b,c  

^a NEW YORK UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYSTEINE; MATRIX PROTEIN; METHIONINE; RIBONUCLEOPROTEIN; VIRUS PHOSPHOPROTEIN;

ANIMAL CELL; ARTICLE; CELL LINE; CELL LINEAGE; CELL LYSATE; CELL MEMBRANE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; ISOELECTRIC FOCUSING; MOUSE; NERVE CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SCINTILLATION; TWO DIMENSIONAL ELECTROPHORESIS; UBIQUITINATION; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS ASSEMBLY; VIRUS NUCLEOCAPSID; VIRUS PARTICLE;

ANIMALS; CELL LINE, TUMOR; HUMANS; INTERFERON-BETA; L CELLS (CELL LINE); MICE; NEUROBLASTOMA; NEURONS; NIH 3T3 CELLS; ORGAN SPECIFICITY; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITINATION; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL MATRIX PROTEINS; VIRAL STRUCTURAL PROTEINS; VIRUS ASSEMBLY;

VESICULAR STOMATITIS VIRUS;

EID: 71449089455     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0057     Document Type: Article

References (57)

1. Barik S, and Banerjee AK: Sequential phosphorylation of the phosphoprotein of vesicular stomatitis virus by cellular and viral protein kinases is essential for transcription activation. J Virol 1992;66:1109-1118.
2. Barr JN, Whelan SP, and Wertz GW: Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus. Biochim Biophys Acta 2002;1577:337-353.
3. Battcock SM, Collier TW, Zu D, and Hirasawa K: Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006;80:4422-4430.
4. Chen M, Ogino T, and Banerjee K: Mapping and functional role of the self-association domain of vesicular stomatitis virus phosphoprotein. J Virol 2006;80:9511-9518.
5. Chong LD, and Rose JK: Membrane association of functional vesicular stomatitis virus matrix protein in vivo. J Virol 1993;67:407-414.
6. Chong LD, and Rose JK: Interactions of normal and mutant vesicular stomatitis virus matrix proteins with the plasma membrane and nucleocapsids. J Virol 1994;68:441-447.
7. Dafny N, and Yang PB: Interferon and the central nervous system. Eur J Pharmacol 2005;523:1-15.
8. Das SC, and Pattnaik AK: Phosphorylation of vesicular stomatitis virus phosphoprotein P is indispensable for virus growth. J Virol 2004;78:6420-6430.
9. Das SC, and Pattnaik AK: Role of the hypervariable hinge region of phosphoprotein P of vesicular stomatitis virus in viral RNA synthesis and assembly of infectious virus particles. J Virol 2005;79:8101-8112.
10. De BP, and Banerjee AK: Specific interactions of vesicular stomatitis virus L and NS proteins with heterologous genome ribonucleoprotein template lead to mRNA synthesis in vitro. J Virol 1984;51:628-634.
11. De BP, and Banerjee AK: Requirements and functions of vesicular stomatitis virus L and NS proteins in the transcription process in vitro. Biochem Biophys Res Commun 1985;126:40-49.
12. Der SD, Zhou A, Williams BR, and Silverman RH: Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 199895:15623-15628.
13. Detje CN, Meyer T, Schmidt H, et al.: Local type I IFN receptor signaling protects against virus spread within the central nervous system. J Immunol 2009;182:2297-2304.
14. Durbin JE, Hackenmiller R, Simon MC, and Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996;84:443-450.
15. Emerson SU, and Yu Y: Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus. J Virol 1975;15:1348-1356.
16. Faria PA, Chakraborty P, Levay A, et al.: VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell 2005;17:93-102.
17. Francoeur AM, Poliquin L, and Stanners CP: The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology 1987;160:236-245.
18. Freed EO: Viral late domains. J Virol 2002;76:4679-4687.
19. Gao Y, and Lenard J: Multimerization and transcriptional activation of the phosphoprotein (P) of vesicular stomatitis virus by casein kinase-II. EMBO J 1995;14:1240-1247.
20. Garcia-Sastre A, and Biron CA: Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006;312: 879-882.
21. Gaudier M, Gaudin Y, and Knossow M: Crystal structure of vesicular stomatitis virus matrix protein. EMBO J 2002;21: 2886-2892.
22. Glodowski DR, Petersen JM, and Dahlberg JE: Complex nuclear localization signals in the matrix protein of vesicular stomatitis virus. J Biol Chem 2002;277:46864-46870.
23. Goodbourn S, Didcock L, and Randall RE: Interferons: cell signaling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000;81:2341-2364.
24. Goodman D, and Matzura H: An improved method of counting radioactive acrylamide gels. Anal Biochem 1971;42: 481-486.
25. Green TJ, Macpherson S, Qiu S, Lebowitz J, Wertz GW, and Luo M: Study of the assembly of vesicular stomatitis virus N protein: role of the P protein. J Virol 2000;74:9515-9524.
26. Gupta AK, and Banerjee AK: Expression and purification of vesicular stomatitis virus N-P complex from Escherichia coli: role in genome RNA transcription and replication in vitro. J Virol 1997;71:4264-4271.
27. Harty RN, Brown ME, McGettigan JP, et al.: Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J Virol 2001;75:10623-10629.
28. Harty RN, Paragas J, Sudol M, and Palese P: A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding. J Virol 1999;73:2921-2929.
29. Hsiang TY, Zhao C, and Krug RM: Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. J Virol 2009;83:5971-5977.
30. Huang S, Hendriks W, Althage A, et al.: Immune response in mice that lack the interferon-gamma receptor. Science 1993;259:1742-1745.
31. Hwang LN, Englund N, Das T, Banerjee AK, and Pattnaik AK: Optimal replication activity of vesicular stomatitis virus RNA polymerase requires phosphorylation of a residue(s) at carboxy-terminal domain II of its accessory subunit, phosphoprotein P. J Virol 1999;73:5613-5620.
32. Ireland DD, and Reiss CS: Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS. Viral Immunol 2006;19:536-545.
33. Jayakar HR, Jeetendra E, and Whitt MA: Rhabdovirus assembly and budding. Virus Res 2004;106:117-132.
34. Jayakar HR, Murti KG, and Whitt MA: Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J Virol 2000;74:9818-9827.
35. Kaptur PE, McKenzie MO, Wertz GW, and Lyles DS: Assembly functions of vesicular stomatitis virus matrix protein are not disrupted by mutations at major sites of phosphorylation. Virology 1995;206:894-903.
36. Katze MG, He Y, and Gale M Jr: Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-687.
37. Kramer MJ, Dennin R, Kramer C, et al.: Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res 1983;3:425-435.
38. Lefrancois L, and Lyles DS: The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of non-neutralizing and crossreactive epitopes of Indiana and New Jersey serotypes. Virology 1982;121:168-174. (Pubitemid 12047216)
39. Lichty BD, McBride H, Hanson S, and Bell JC: Matrix protein of vesicular stomatitis virus harbours a cryptic mitochondrial- targeting motif. J Gen Virol 2006;87:3379-3384.
40. Little LM, Zavada J, Der CJ, and Huang AS: Identity of HeLa cell determinants acquired by vesicular stomatitis virus with a tumor antigen. Science 1983;220:1069-1071.
41. MaheshwariRK,DemseyAE,Mohanty SB, and Friedman RM: Interferon-treated cells release vesicular stomatitis virus particles lacking glycoprotein spikes: correlationwith biochemical data. Proc Natl Acad Sci USA 1980;77:2284-2287.
42. Masters PS, and Banerjee AK: Complex formation with vesicular stomatitis virus phosphoprotein NS prevents binding of nucleocapsid protein N to nonspecific RNA. J Virol 1988;62:2658-2664.
43. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, and AguetM: Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-1921.
44. Ogden JR, Pal R, and Wagner RR: Mapping regions of the matrix protein of vesicular stomatitis virus which bind to ribonucleocapsids, liposomes, and monoclonal antibodies. J Virol 1986;58:860-868.
45. Okumura A, Pitha PM, and Harty RN: ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci USA 2008;105:3974-3979.
46. Perlman SM, and Huang AS: RNA synthesis of vesicular stomatitis virus. V. Interactions between transcription and replication. J Virol 1973;12:1395-1400.
47. Petersen JM, Her LS, Varvel V, Lund E, and Dahlberg JE: The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 2000;20:8590-8601.
48. Raiborg C, and Stenmark H: The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 2009;458:445-452.
49. Shestakova E, Bandu MT, Doly J, and Bonnefoy E: Inhibition of histone deacetylation induces constitutive derepression of the beta interferon promoter and confers antiviral activity. J Virol 2001;75:3444-5342.
50. Taylor GM,Hanson PI, andKielianM:Ubiquitin depletion and dominant-negative VPS4 inhibit rhabdovirus budding without affecting alphavirus budding. J Virol 2007;81:13631-13639.
51. Trottier MD, Lyles DS, and Reiss CS: Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol 2007;13:433-445.
52. Trottier MDJ, Palian BM, and Shoshkes Reiss C: VSV replication in neurons is inhibited by type I IFN at multiple stages of infection. Virology 2005;333:215-225.
53. Truckenmiller ME, Tornatore C, Wright RD, Dillon-Carter O, Meiners S, Geller HM, and Freed WJ: A truncated SV40 large T antigen lacking the p53 binding domain overcomes p53-induced growth arrest and immortalizes primary mesencephalic cells. Cell Tissue Res 1998;291:175-189.
54. van den Broek MF, Muller U, Huang S, Aguet M, and Zinkernagel RM: Antiviral defense in mice lacking both alpha/ beta andgamma interferonreceptors. JVirol 1995;69:4792-4796.
55. Vogel SN, and Fertsch D: Macrophages from endotoxinhyporesponsive (Lpsd) C3H/HeJ mice are permissive for vesicular stomatitis virus because of reduced levels of endogenous interferon: possible mechanism for natural resistance to virus infection. J Virol 1987;61:812-818.
56. Wertz GW, Whelan S, LeGrone A, and Ball LA: Extent of terminal complementarity modulates the balance between transcription and replication of vesicular stomatitis virus RNA. Proc Natl Acad Sci USA 1994;91:8587-8591.
57. Wong PK, Yuen PH, MacLeod R, Chang EH,MyersMW, and Friedman RM: The effect of interferon on de novo infection of Moloney murine leukemia virus. Cell 1977;10:245-252